Ceribell Inc

CBLL is in a Stage 3 Distribution phase with price failing to track above declining short EMAs and volume skewed to downside, confirming distribution dynamics. The medium-term bias is bearish, and current price action shows continuation below the 9/21 EMA cluster, making execution timing favorable for the short side. We'll sell now on the breakdown below the declining EMA zone, targeting continuation participation. Key risks include potential support at the 50 DMA and 200 DMA stalling the decline and any reclaim of EMAs invalidating the bearish posture.

• ↑Q1 2026 revenue rose 29% YoY to $26.5M
• ↑Active hospital accounts grew to 680, just 3% penetrated
• ↓Q1 net loss expanded to $19.7M, deepening annual deficits